Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo.

Musi E, Schwartz GK, Yoo JH, Odelberg SJ, Li DY, Bonner MY, Selvakumar P, Rao S, Gilbert LC, Elsey J, Arbiser JL.

Oncotarget. 2019 Jul 8;10(43):4424-4436. doi: 10.18632/oncotarget.27040. eCollection 2019 Jul 8.

2.

Selenium unmasks protective iron armor: A possible defense against cutaneous inflammation and cancer.

Arbiser JL, Bonner MY, Ward N, Elsey J, Rao S.

Biochim Biophys Acta Gen Subj. 2018 May 28. pii: S0304-4165(18)30150-8. doi: 10.1016/j.bbagen.2018.05.018. [Epub ahead of print]

PMID:
29852199
3.

Evidence for biochemical barrier restoration: Topical solenopsin analogs improve inflammation and acanthosis in the KC-Tie2 mouse model of psoriasis.

Arbiser JL, Nowak R, Michaels K, Skabytska Y, Biedermann T, Lewis MJ, Bonner MY, Rao S, Gilbert LC, Yusuf N, Karlsson I, Fritz Y, Ward NL.

Sci Rep. 2017 Sep 11;7(1):11198. doi: 10.1038/s41598-017-10580-y.

4.

Targeting the duality of cancer.

Arbiser JL, Bonner MY, Gilbert LC.

NPJ Precis Oncol. 2017;1. pii: 23. doi: 10.1038/s41698-017-0026-x. Epub 2017 Jun 22.

5.

Activation of tumor suppressor LKB1 by honokiol abrogates cancer stem-like phenotype in breast cancer via inhibition of oncogenic Stat3.

Sengupta S, Nagalingam A, Muniraj N, Bonner MY, Mistriotis P, Afthinos A, Kuppusamy P, Lanoue D, Cho S, Korangath P, Shriver M, Begum A, Merino VF, Huang CY, Arbiser JL, Matsui W, Győrffy B, Konstantopoulos K, Sukumar S, Marignani PA, Saxena NK, Sharma D.

Oncogene. 2017 Oct 12;36(41):5709-5721. doi: 10.1038/onc.2017.164. Epub 2017 Jun 5.

6.

Activation of Protein Kinase C ε in Merkel Cell Polyomavirus-Induced Merkel Cell Carcinoma.

Costa A, Mackelfresh J, Gilbert L, Bonner MY, Arbiser JL.

JAMA Dermatol. 2017 Sep 1;153(9):931-932. doi: 10.1001/jamadermatol.2017.1296. No abstract available.

7.

Erratum to: Honokiol activates AMP-activated protein kinase in breast cancer cells via LKB1-dependent pathway and inhibits breast carcinogenesis.

Nagalingam A, Arbiser JL, Bonner MY, Saxena NK, Sharma D.

Breast Cancer Res. 2017 Mar 28;19(1):39. doi: 10.1186/s13058-017-0829-2. No abstract available.

8.

Honokiol protects skin cells against inflammation, collagenolysis, apoptosis, and senescence caused by cigarette smoke damage.

Costa A, Facchini G, Pinheiro ALTA, da Silva MS, Bonner MY, Arbiser J, Eberlin S.

Int J Dermatol. 2017 Jul;56(7):754-761. doi: 10.1111/ijd.13569. Epub 2017 Feb 22.

9.

SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis.

Akamata K, Wei J, Bhattacharyya M, Cheresh P, Bonner MY, Arbiser JL, Raparia K, Gupta MP, Kamp DW, Varga J.

Oncotarget. 2016 Oct 25;7(43):69321-69336. doi: 10.18632/oncotarget.12504.

10.

Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies.

Mędra A, Witkowska M, Majchrzak A, Cebula-Obrzut B, Bonner MY, Robak T, Arbiser JL, Smolewski P.

Molecules. 2016 Jul 30;21(8). pii: E995. doi: 10.3390/molecules21080995.

11.

Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia.

Laidlaw KM, Berhan S, Liu S, Silvestri G, Holyoake TL, Frank DA, Aggarwal B, Bonner MY, Perrotti D, Jørgensen HG, Arbiser JL.

Oncotarget. 2016 Aug 9;7(32):51651-51664. doi: 10.18632/oncotarget.10541.

12.

Tris DBA palladium is highly effective against growth and metastasis of pancreatic cancer in an orthotopic model.

Díaz B, Ostapoff KT, Toombs JE, Lo J, Bonner MY, Curatolo A, Adsay V, Brekken RA, Arbiser JL.

Oncotarget. 2016 Aug 9;7(32):51569-51580. doi: 10.18632/oncotarget.10514.

13.

Use of Polyphenolic Compounds in Dermatologic Oncology.

Costa A, Bonner MY, Arbiser JL.

Am J Clin Dermatol. 2016 Aug;17(4):369-85. doi: 10.1007/s40257-016-0193-5. Review.

14.

Seborrheic Keratoses: The Rodney Dangerfield of Skin lesions, and Why They Should Get Our Respect.

Arbiser JL, Bonner MY.

J Invest Dermatol. 2016 Mar;136(3):564-566. doi: 10.1016/j.jid.2015.12.019.

15.

Tuberculosis verrucosa cutis lesions exhibit a greater microvessel count than lupus vulgaris lesions.

Bhandarkar SS, Lanka P, Lanka LR, Veledar E, Bonner MY, MacKelfresh J, Arbiser JL.

Exp Dermatol. 2016 Jun;25(6):479-80. doi: 10.1111/exd.12980. Epub 2016 May 12. No abstract available.

16.

Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo.

Bonner MY, Karlsson I, Rodolfo M, Arnold RS, Vergani E, Arbiser JL.

Oncotarget. 2016 Mar 15;7(11):12857-68. doi: 10.18632/oncotarget.7289.

17.

Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer.

Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, Sharma D.

Oncotarget. 2015 Oct 6;6(30):29947-62. doi: 10.18632/oncotarget.4937.

18.

Honokiol abrogates leptin-induced tumor progression by inhibiting Wnt1-MTA1-β-catenin signaling axis in a microRNA-34a dependent manner.

Avtanski DB, Nagalingam A, Kuppusamy P, Bonner MY, Arbiser JL, Saxena NK, Sharma D.

Oncotarget. 2015 Jun 30;6(18):16396-410.

19.

Solenopsin A and analogs exhibit ceramide-like biological activity.

Karlsson I, Zhou X, Thomas R, Smith AT, Bonner MY, Bakshi P, Banga AK, Bowen JP, Qabaja G, Ford SL, Ballard MD, Petersen KS, Li X, Chen G, Ogretmen B, Zhang J, Watkins EB, Arnold RS, Arbiser JL.

Vasc Cell. 2015 May 8;7:5. doi: 10.1186/s13221-015-0030-2. eCollection 2015.

20.

Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3.

Pillai VB, Samant S, Sundaresan NR, Raghuraman H, Kim G, Bonner MY, Arbiser JL, Walker DI, Jones DP, Gius D, Gupta MP.

Nat Commun. 2015 Apr 14;6:6656. doi: 10.1038/ncomms7656.

21.

Inactivation of NADPH oxidases NOX4 and NOX5 protects human primary fibroblasts from ionizing radiation-induced DNA damage.

Weyemi U, Redon CE, Aziz T, Choudhuri R, Maeda D, Parekh PR, Bonner MY, Arbiser JL, Bonner WM.

Radiat Res. 2015 Mar;183(3):262-70. doi: 10.1667/RR13799.1. Epub 2015 Feb 23.

22.

NADPH oxidase 4 is a critical mediator in Ataxia telangiectasia disease.

Weyemi U, Redon CE, Aziz T, Choudhuri R, Maeda D, Parekh PR, Bonner MY, Arbiser JL, Bonner WM.

Proc Natl Acad Sci U S A. 2015 Feb 17;112(7):2121-6. doi: 10.1073/pnas.1418139112. Epub 2015 Feb 2.

23.

The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer.

Bonner MY, Arbiser JL.

Future Med Chem. 2014;6(12):1413-22. doi: 10.4155/fmc.14.86. Review.

24.

Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.

Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, Sharma D.

Mol Oncol. 2014 May;8(3):565-80. doi: 10.1016/j.molonc.2014.01.004. Epub 2014 Jan 15.

25.

Honokiol inhibits androgen receptor activity in prostate cancer cells.

Hahm ER, Karlsson AI, Bonner MY, Arbiser JL, Singh SV.

Prostate. 2014 Apr;74(4):408-20. doi: 10.1002/pros.22762. Epub 2013 Dec 11.

26.

Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78.

Martin S, Lamb HK, Brady C, Lefkove B, Bonner MY, Thompson P, Lovat PE, Arbiser JL, Hawkins AR, Redfern CP.

Br J Cancer. 2013 Jul 23;109(2):433-43. doi: 10.1038/bjc.2013.325. Epub 2013 Jun 27.

27.

In vivo Gram staining of tinea versicolor.

Spence-Shishido A, Carr C, Bonner MY, Arbiser JL.

JAMA Dermatol. 2013 Aug;149(8):991-2. doi: 10.1001/jamadermatol.2013.2699. No abstract available.

28.

Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases.

Arbiser JL, Bips M, Seidler A, Bonner MY, Kovach C.

J Am Acad Dermatol. 2012 Aug;67(2):e81-3. doi: 10.1016/j.jaad.2011.10.028. No abstract available.

29.

Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia.

Govindarajan B, Willoughby L, Band H, Curatolo AS, Veledar E, Chen S, Bonner MY, Abel MG, Moses MA, Arbiser JL.

Vasc Cell. 2012 Jul 5;4(1):11. doi: 10.1186/2045-824X-4-11.

30.

Targeting NADPH oxidases for the treatment of cancer and inflammation.

Bonner MY, Arbiser JL.

Cell Mol Life Sci. 2012 Jul;69(14):2435-42. doi: 10.1007/s00018-012-1017-2. Epub 2012 May 13. Review.

31.

Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma.

Munson JM, Fried L, Rowson SA, Bonner MY, Karumbaiah L, Diaz B, Courtneidge SA, Knaus UG, Brat DJ, Arbiser JL, Bellamkonda RV.

Sci Transl Med. 2012 Mar 28;4(127):127ra36. doi: 10.1126/scitranslmed.3003016.

32.
33.

Posterior lumbar vein off the retrohepatic inferior vena cava: a novel anatomical variant with surgical implications.

Abbasi A, Johnson TV, Kleris R, Ying K, Bonner MY, Maithel SK, Kooby DA, Marshall FF, Master VA.

J Urol. 2012 Jan;187(1):296-301. doi: 10.1016/j.juro.2011.09.009. Epub 2011 Nov 17.

PMID:
22099996
34.

High level expression of angiopoietin-2 in human abscesses.

Bartus C, Brown LF, Bonner MY, Arbiser JL.

J Am Acad Dermatol. 2011 Jan;64(1):200-1. doi: 10.1016/j.jaad.2010.02.025. No abstract available.

35.

Hemangiomas, angiosarcomas, and vascular malformations represent the signaling abnormalities of pathogenic angiogenesis.

Arbiser JL, Bonner MY, Berrios RL.

Curr Mol Med. 2009 Nov;9(8):929-34. Review.

PMID:
19925405
36.

Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice.

Bhandarkar SS, Jaconi M, Fried LE, Bonner MY, Lefkove B, Govindarajan B, Perry BN, Parhar R, Mackelfresh J, Sohn A, Stouffs M, Knaus U, Yancopoulos G, Reiss Y, Benest AV, Augustin HG, Arbiser JL.

J Clin Invest. 2009 Aug;119(8):2359-65. doi: 10.1172/JCI33877. Epub 2009 Jul 13.

37.

Melanomas reveal their nakedness: uncovered by interferon alfa.

Arbiser JL, Bonner MY.

Arch Dermatol. 2009 May;145(5):587-8. doi: 10.1001/archdermatol.2009.76. No abstract available.

PMID:
19451506

Supplemental Content

Loading ...
Support Center